The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hamada, N.
Right arrow Articles by Nakanishi, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hamada, N.
Right arrow Articles by Nakanishi, Y.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*BLEOMYCIN
Medline Plus Health Information
*Genes and Gene Therapy
*Pulmonary Fibrosis
The Journal of Immunology, 2005, 175: 1224-1231.
Copyright © 2005 by The American Association of Immunologists

Anti-Vascular Endothelial Growth Factor Gene Therapy Attenuates Lung Injury and Fibrosis in Mice1

Naoki Hamada*, Kazuyoshi Kuwano2,*, Mizuho Yamada*, Naoki Hagimoto*, Kenichi Hiasa{dagger}, Kensuke Egashira{dagger}, Nobutaka Nakashima*, Takashige Maeyama*, Michihiro Yoshimi* and Yoichi Nakanishi*

* Research Institute for Diseases of the Chest,{dagger} Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Vascular endothelial growth factor (VEGF) is an angiogenesis factor with proinflammatory roles. Flt-1 is one of the specific receptors for VEGF, and soluble flt-1 (sflt-1) binds to VEGF and competitively inhibits it from binding to the receptors. We examined the role of VEGF in the pathophysiology of bleomycin-induced pneumopathy in mice, using a new therapeutic strategy that comprises transfection of the sflt-1 gene into skeletal muscles as a biofactory for anti-VEGF therapy. The serum levels of sflt-1 were significantly increased at 3–14 days after the gene transfer. Transfection of the sflt-1 gene at 3 days before or 7 days after the intratracheal instillation of bleomycin decreased the number of inflammatory cells, the protein concentration in the bronchoalveolar lavage fluid and with von Willebrand factor expression at 14 days. Transfection of the sflt-1 gene also attenuated pulmonary fibrosis and apoptosis at 14 days. Since the inflammatory cell infiltration begins at 3 days and is followed by interstitial fibrosis, it is likely that VEGF has important roles as a proinflammatory, a permeability-inducing, and an angiogenesis factor not only in the early inflammatory phase but also in the late fibrotic phase. Furthermore, this method may be beneficial for treating lung injury and fibrosis from the viewpoint of clinical application, since it does not require the use of a viral vector or neutralizing Ab.




This article has been cited by other articles:


Home page
ThoraxHome page
R Borie, A Fabre, F Prost, J Marchal-Somme, R Lebtahi, S Marchand-Adam, M Aubier, P Soler, and B Crestani
Activation of somatostatin receptors attenuates pulmonary fibrosis
Thorax, March 1, 2008; 63(3): 251 - 258.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
A. L. Mora, E. Torres-Gonzalez, M. Rojas, J. Xu, J. Ritzenthaler, S. H. Speck, J. Roman, K. Brigham, and A. Stecenko
Control of Virus Reactivation Arrests Pulmonary Herpesvirus-induced Fibrosis in IFN-{gamma} Receptor-deficient Mice
Am. J. Respir. Crit. Care Med., June 1, 2007; 175(11): 1139 - 1150.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
N. I. Chaudhary, G. J. Roth, F. Hilberg, J. Muller-Quernheim, A. Prasse, G. Zissel, A. Schnapp, and J. E. Park
Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis
Eur. Respir. J., May 1, 2007; 29(5): 976 - 985.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Cao, P. Sonveaux, S. Liu, Y. Zhao, J. Mi, B. M. Clary, C.-Y. Li, C. D. Kontos, and M. W. Dewhirst
Systemic Overexpression of Angiopoietin-2 Promotes Tumor Microvessel Regression and Inhibits Angiogenesis and Tumor Growth
Cancer Res., April 15, 2007; 67(8): 3835 - 3844.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
F. J. Martinez and M. P. Keane
Update in diffuse parenchymal lung diseases 2005.
Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1066 - 1071.
[Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
N. F. Voelkel, R. W. Vandivier, and R. M. Tuder
Vascular endothelial growth factor in the lung
Am J Physiol Lung Cell Mol Physiol, February 1, 2006; 290(2): L209 - L221.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.